All Dezima articles
-
Business
Amgen expands cardiovascular portfolio with Dezima acquisition
Amgen’s $300 million purchase of Dutch biotech gives the company the potential to offer more varied treatment options to lower cholesterol
Amgen’s $300 million purchase of Dutch biotech gives the company the potential to offer more varied treatment options to lower cholesterol